Dr. Daniel H. Ahn, D.O.
Hematology & Oncology (Hematology & Oncology Physician)
13400 E Shea Blvd
Scottsdale, AZ 85259
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of North Texas Hsc, College of Osteopathic Med (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 680
Licensed in Texas since 2011, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: University of North Texas Hsc, College of Osteopathic Med
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
AZ license 006924 · TX license N9156 (first issued 2011; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mayo Clinic Hospital Phoenix, AZ
Medical groups
- Mayo Clinic Arizona (1,626 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 680
- Services billed
- 94,216
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 11,160 | 52 |
| Injection, pembrolizumab, 1 mg | 7,404 | 33 |
| Injection, nivolumab, 1 mg | 6,880 | 13 |
| Injection, fosaprepitant, 1 mg | 5,850 | 35 |
| Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 4,800 | 12 |
| Injection, oxaliplatin, 0.5 mg | 4,340 | 12 |
| Injection, paclitaxel, 1 mg | 2,400 | 16 |
| Injection, denosumab, 1 mg | 1,980 | 18 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,630 | 20 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 1,245 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in Scottsdale, AZ | 70 |
| Ondansetron Hcl Other prescribers in Scottsdale, AZ | 45 |
| Tramadol Hcl Other prescribers in Scottsdale, AZ | 25 |
| Dexamethasone Other prescribers in Scottsdale, AZ | 23 |
| Creon (lipase/protease/amylase) Other prescribers in Scottsdale, AZ | 23 |
| Eliquis (apixaban) Other prescribers in Scottsdale, AZ | 20 |
| Ondansetron Odt (ondansetron) Other prescribers in Scottsdale, AZ | 20 |
| Lonsurf (trifluridine/tipiracil hcl) | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 13 payments worth $8,707 in total to this clinician.
| Exelixis Inc. | $4,827 |
|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,538 |
| Bayer HealthCare Pharmaceuticals Inc. | $1,082 |
| Incyte Corporation | $133 |
| Tempus Ai, Inc | $127 |
| Consulting Fee | $7,579 |
|---|---|
| Food and Beverage | $1,128 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Exelixis Inc. Dec 4, 2025 | Consulting Fee | $3,960 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Aug 28, 2025 | Consulting Fee | $2,538 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 5, 2025 | Consulting Fee Stivarga · Oncology | $1,082 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $212,755 in research payments for these studies, mostly to the institutions running them.
- Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Mirati Therapeutics, Inc. · Active, not recruiting · NCT04793958 - A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care gemcitabine, cisplatin, and durvalumab for first line locally advanced or metastatic HER2-expressing Biliary Tract Cancer
AstraZeneca Pharmaceuticals LP - A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination with Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Alnylam Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.